Vaccine Adjuvants Market by Application and Geography

Global Vaccine Adjuvants Market: About this market
The vaccine adjuvants market analysis considers sales from infectious diseases, cancer, and other diseases. Our study also finds the sales of vaccine adjuvants in Asia, Europe, North America, and ROW. In 2019, the infectious diseases segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as R&D activities for the formulation of novel adjuvants to prevent the spread of infectious diseases will play a significant role in the infectious diseases segment to maintain its market position. Also, our global vaccine adjuvants market report looks at factors such as increasing use of adjuvants in vaccines, growing support of government in R&D, and initiatives to increase awareness of immunization programs and access to vaccines. However, side effects of adjuvants, inherent limitations of adjuvants, and safety concerns associated with vaccine adjuvants may hamper the growth of the vaccine adjuvants industry over the forecast period.

Global Vaccine Adjuvants Market: Overview

Initiatives to increase awareness of immunization programs and access to vaccines
Infants and children are prone to deadly diseases like hepatitis B, measles, and tetanus, which can cause serious harm. The lack of immunization awareness can lead to the propagation of such deadly diseases when simple measures could eradicate them completely. Therefore, raising awareness about immunization programs and increasing the access to vaccines is important. Awareness campaigns such as the World Immunization Week are celebrated at the end of April every year to raise awareness about how immunization and vaccination can fight against a host of diseases. Such initiatives will lead to the expansion of the global vaccine adjuvants market at a CAGR of almost 11% during the forecast period.

Development of nanoparticle adjuvants
Nanotechnology offers a multifunctional stage for the integration of desired adjuvant activities. Due to the high efficacy of vaccine adjuvants in potentiating a strong immune response in individuals, vendors are focusing on developing new-generation adjuvants to create a more potent antigen-specific response. Nanoparticles for antigen delivery can provide high bioavailability as well as constant and controlled-release profiles. Moreover, the immune-regulating activity of nanoparticles can further promote and shape cellular and humoral immune responses. Therefore, the combination of delivery functions and immunomodulatory effects of nanoparticles as adjuvants is expected to benefit the immune outcomes of vaccination largely. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few major players, the global vaccine adjuvants market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading vaccine adjuvants manufacturers, that include Agenus Inc., Avanti Polar Lipids Inc., Croda International Plc, CSL Ltd., GlaxoSmithKline Plc, InvivoGen, Merck KGaA, OZ Biosciences SAS, SEPPIC SA, and Vaxine Pty Ltd..

Also, the vaccine adjuvants market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

Preface
Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Parent market
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2019
Market size and forecast 2019-2024
Market Outlook

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application
Comparison by application
Infectious diseases - Market size and forecast 2019-2024
Cancer - Market size and forecast 2019-2024
Other diseases - Market size and forecast 2019-2024
Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2019-2024
Europe - Market size and forecast 2019-2024
Asia - Market size and forecast 2019-2024
ROW - Market size and forecast 2019-2024
Key leading countries
Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 11: MARKET TRENDS

Increase in R&D of novel vaccine adjuvants
Development of nanoparticle adjuvants
Rising number of collaborations

PART 12: VENDOR LANDSCAPE

Overview
Landscape disruption
Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Agenus Inc.
Avanti Polar Lipids Inc.
Croda International Plc
CSL Ltd.
GlaxoSmithKline Plc
InvivoGen
Merck KGaA
OZ Biosciences SAS
SEPPIC SA
Vaxine Pty Ltd.

PART 14: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors

List of Exhibits

Exhibit 01: Vendor key offerings
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Application - Market share 2019-2024 (%)
Exhibit 19: Comparison by application
Exhibit 20: Infectious diseases - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Infectious diseases - Year-over-year growth 2020-2024 (%)
Exhibit 22: Cancer - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Cancer - Year-over-year growth 2020-2024 (%)
Exhibit 24: Other diseases - Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Other diseases - Year-over-year growth 2020-2024 (%)
Exhibit 26: Market opportunity by application
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2019-2024 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 31: North America - Year-over-year growth 2020-2024 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Agenus Inc. - Vendor overview
Exhibit 51: Agenus Inc. - Business segments
Exhibit 52: Agenus Inc. - Organizational developments
Exhibit 53: Agenus Inc. - Geographic focus
Exhibit 54: Agenus Inc. - Key offerings
Exhibit 55: Agenus Inc. - Key customers
Exhibit 56: Avanti Polar Lipids Inc. - Vendor overview
Exhibit 57: Avanti Polar Lipids Inc. - Business segments
Exhibit 58: Avanti Polar Lipids Inc. - Organizational developments
Exhibit 59: Avanti Polar Lipids Inc. - Key offerings
Exhibit 60: Avanti Polar Lipids Inc. - Key customers
Exhibit 61: Croda International Plc - Vendor overview
Exhibit 62: Croda International Plc - Business segments
Exhibit 63: Croda International Plc - Organizational developments
Exhibit 64: Croda International Plc - Geographic focus
Exhibit 65: Croda International Plc - Segment focus
Exhibit 66: Croda International Plc - Key offerings
Exhibit 67: Croda International Plc - Key customers
Exhibit 68: CSL Ltd. - Vendor overview
Exhibit 69: CSL Ltd. - Business segments
Exhibit 70: CSL Ltd. - Organizational developments
Exhibit 71: CSL Ltd. - Geographic focus
Exhibit 72: CSL Ltd. - Segment focus
Exhibit 73: CSL Ltd. - Key offerings
Exhibit 74: CSL Ltd. - Key customers
Exhibit 75: GlaxoSmithKline Plc - Vendor overview
Exhibit 76: GlaxoSmithKline Plc - Business segments
Exhibit 77: GlaxoSmithKline Plc - Organizational developments
Exhibit 78: GlaxoSmithKline Plc - Geographic focus
Exhibit 79: GlaxoSmithKline Plc - Segment focus
Exhibit 80: GlaxoSmithKline Plc - Key offerings
Exhibit 81: GlaxoSmithKline Plc - Key customers
Exhibit 82: InvivoGen - Vendor overview
Exhibit 83: InvivoGen - Product segments
Exhibit 84: InvivoGen - Key offerings
Exhibit 85: InvivoGen - Key customers
Exhibit 86: Merck KGaA - Vendor overview
Exhibit 87: Merck KGaA - Business segments
Exhibit 88: Merck KGaA - Organizational developments
Exhibit 89: Merck KGaA - Geographic focus
Exhibit 90: Merck KGaA - Segment focus
Exhibit 91: Merck KGaA - Key offerings
Exhibit 92: Merck KGaA - Key customers
Exhibit 93: OZ Biosciences SAS - Vendor overview
Exhibit 94: OZ Biosciences SAS - Product segments
Exhibit 95: OZ Biosciences SAS - Key offerings
Exhibit 96: OZ Biosciences SAS - Key customers
Exhibit 97: SEPPIC SA - Vendor overview
Exhibit 98: SEPPIC SA - Product segments
Exhibit 99: SEPPIC SA - Organizational developments
Exhibit 100: SEPPIC SA - Key offerings
Exhibit 101: SEPPIC SA - Key customers
Exhibit 102: Vaxine Pty Ltd. - Vendor overview
Exhibit 103: Vaxine Pty Ltd. - Business segments
Exhibit 104: Vaxine Pty Ltd. - Key offerings
Exhibit 105: Vaxine Pty Ltd. - Key customers
Exhibit 106: Validation techniques employed for market sizing
Exhibit 107: Definition of market positioning of vendors

Executive Summary

The following companies as the key players in the global vaccine adjuvants market: Agenus Inc., Avanti Polar Lipids Inc., Croda International Plc, CSL Ltd., GlaxoSmithKline Plc, InvivoGen, Merck KGaA, OZ Biosciences SAS, SEPPIC SA, and Vaxine Pty Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanoparticle adjuvants.”

According to the report, one of the major drivers for this market is the initiatives to increase awareness of immunization programs and access to vaccines.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of adjuvants.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.